Literature DB >> 16988262

Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice.

Julianne E Rollenhagen1, Anuj Kalsy, Francisca Cerda, Manohar John, Jason B Harris, Regina C Larocque, Firdausi Qadri, Stephen B Calderwood, Ronald K Taylor, Edward T Ryan.   

Abstract

Toxin-coregulated pilin A (TcpA) is the main structural subunit of a type IV bundle-forming pilus of Vibrio cholerae, the cause of cholera. Toxin-coregulated pilus is involved in formation of microcolonies of V. cholerae at the intestinal surface, and strains of V. cholerae deficient in TcpA are attenuated and unable to colonize intestinal surfaces. Anti-TcpA immunity is common in humans recovering from cholera in Bangladesh, and immunization against TcpA is protective in murine V. cholerae models. To evaluate whether transcutaneously applied TcpA is immunogenic, we transcutaneously immunized mice with 100 mug of TcpA or TcpA with an immunoadjuvant (cholera toxin [CT], 50 mug) on days 0, 19, and 40. Mice immunized with TcpA alone did not develop anti-TcpA responses. Mice that received transcutaneously applied TcpA and CT developed prominent anti-TcpA immunoglobulin G (IgG) serum responses but minimal anti-TcpA IgA. Transcutaneous immunization with CT induced prominent IgG and IgA anti-CT serum responses. In an infant mouse model, offspring born to dams transcutaneously immunized either with TcpA and CT or with CT alone were challenged with 10(6) CFU (one 50% lethal dose) wild-type V. cholerae O1 El Tor strain N16961. At 48 h, mice born to females transcutaneously immunized with CT alone had 36% +/- 10% (mean +/- standard error of the mean) survival, while mice born to females transcutaneously immunized with TcpA and CT had 69% +/- 6% survival (P < 0.001). Our results suggest that transcutaneous immunization with TcpA and an immunoadjuvant induces protective anti-TcpA immune responses. Anti-TcpA responses may contribute to an optimal cholera vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988262      PMCID: PMC1594919          DOI: 10.1128/IAI.00438-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Domains within the Vibrio cholerae toxin coregulated pilin subunit that mediate bacterial colonization.

Authors:  D Sun; M J Lafferty; J A Peek; R K Taylor
Journal:  Gene       Date:  1997-06-11       Impact factor: 3.688

2.  Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains.

Authors:  T I Crean; M John; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Virulence and the environment: a novel role for Vibrio cholerae toxin-coregulated pili in biofilm formation on chitin.

Authors:  Gemma Reguera; Roberto Kolter
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

4.  Skin immunization made possible by cholera toxin.

Authors:  G M Glenn; M Rao; G R Matyas; C R Alving
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

5.  Differential transcription of the tcpPH operon confers biotype-specific control of the Vibrio cholerae ToxR virulence regulon.

Authors:  Y M Murley; P A Carroll; K Skorupski; R K Taylor; S B Calderwood
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria.

Authors:  D K Karaolis; S Somara; D R Maneval; J A Johnson; J B Kaper
Journal:  Nature       Date:  1999-05-27       Impact factor: 49.962

7.  In vitro and in vivo analyses of constitutive and in vivo-induced promoters in attenuated vaccine and vector strains of Vibrio cholerae.

Authors:  M John; T I Crean; S B Calderwood; E T Ryan
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  Phase variation in tcpH modulates expression of the ToxR regulon in Vibrio cholerae.

Authors:  P A Carroll; K T Tashima; M B Rogers; V J DiRita; S B Calderwood
Journal:  Mol Microbiol       Date:  1997-09       Impact factor: 3.501

9.  Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants.

Authors:  G M Glenn; T Scharton-Kersten; R Vassell; G R Matyas; C R Alving
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

10.  In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.

Authors:  E T Ryan; T I Crean; M John; J R Butterton; J D Clements; S B Calderwood
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

View more
  18 in total

1.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

2.  Transcutaneous immunization with a synthetic hexasaccharide-protein conjugate induces anti-Vibrio cholerae lipopolysaccharide responses in mice.

Authors:  Julianne E Rollenhagen; Anuj Kalsy; Rina Saksena; Alaullah Sheikh; Mohammad Murshid Alam; Firdausi Qadri; Stephen B Calderwood; Pavol Kovác; Edward T Ryan
Journal:  Vaccine       Date:  2009-06-27       Impact factor: 3.641

3.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

4.  The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.

Authors:  Leslie M Mayo-Smith; Jakub K Simon; Wilbur H Chen; Douglas Haney; Michael Lock; Caroline E Lyon; Stephen B Calderwood; Beth D Kirkpatrick; Mitchell Cohen; Myron M Levine; Marc Gurwith; Jason B Harris
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

5.  Vibrio cholerae El Tor TcpA crystal structure and mechanism for pilus-mediated microcolony formation.

Authors:  Mindy S Lim; Dixon Ng; ZuSheng Zong; Andrew S Arvai; Ronald K Taylor; John A Tainer; Lisa Craig
Journal:  Mol Microbiol       Date:  2010-06-01       Impact factor: 3.501

6.  Dissecting serotype-specific contributions to live oral cholera vaccine efficacy.

Authors:  Brandon Sit; Bolutife Fakoya; Ting Zhang; Gabriel Billings; Matthew K Waldor
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

7.  Expression of toxin co-regulated pilus subunit A (TCPA) of Vibrio cholerae and its immunogenic epitopes fused to cholera toxin B subunit in transgenic tomato (Solanum lycopersicum).

Authors:  Manoj Kumar Sharma; Nirmal Kumar Singh; Dewal Jani; Rama Sisodia; M Thungapathra; J K Gautam; L S Meena; Yogendra Singh; Amit Ghosh; Akhilesh Kumar Tyagi; Arun Kumar Sharma
Journal:  Plant Cell Rep       Date:  2007-10-26       Impact factor: 4.570

8.  A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh.

Authors:  Fahima Chowdhury; Ashraful I Khan; Jason B Harris; Regina C LaRocque; Mohiul Islam Chowdhury; Edward T Ryan; A S G Faruque; Stephen B Calderwood; Firdausi Qadri
Journal:  Pediatr Infect Dis J       Date:  2008-11       Impact factor: 2.129

9.  Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.

Authors:  A A Tarique; A Kalsy; M Arifuzzaman; S M Rollins; R C Charles; D T Leung; J B Harris; R C Larocque; A Sheikh; M S Bhuiyan; R Saksena; J D Clements; S B Calderwood; F Qadri; P Kovác; E T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-02-22

10.  Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae.

Authors:  L A Novotny; J D Clements; L O Bakaletz
Journal:  Mucosal Immunol       Date:  2011-02-16       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.